Current Research Studies

Cancer – ANBL1531: Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Condition or Therapy:

High-risk neuroblastoma (HR-NBL), ganglioneuroblastoma

Category:

Cancer and Blood Disorders
Study Number: ANBL1531

What is the goal of this study?

Researchers want to determine whether the event-free survival rate of high-risk neuroblastoma is improved with the addition of iobenguane I-131 (I-MIBG) during chemotherapy.

Who can join the study?

This study may be a good fit for children and young adults who:

  • are 1 to 30 years old, and
  • have been newly diagnosed with neuroblastoma or ganglioneuroblastoma.

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins